<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015248</url>
  </required_header>
  <id_info>
    <org_study_id>MALT2008-01</org_study_id>
    <secondary_id>No EudraCT: 2008-007725-39</secondary_id>
    <nct_id>NCT01015248</nct_id>
  </id_info>
  <brief_title>Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma</brief_title>
  <official_title>Multicentric, Non-Randomized Phase 2 Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the therapeutic activity and safety of the combination of
      Bendamustine and Rituximab in MALT lymphomas.

      Primary endpoint:

        -  Event-free-survival (EFS) (failure or death from any cause) for all patients.

      Secondary endpoints:

        -  Complete and partial remission rates for all patients

        -  Response duration (time to relapse or progression) for responder patients

        -  Progression-free-survival (PFS) (disease progression or death from lymphoma: for all
           patients

        -  Overall survival for all patients

        -  Acute and long-term toxicity
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of assessment is the event-free-survival (EFS) according to the criteria of the International Workshop to Standardize Response Criteria for NHL and Criteria for evaluation of response in NHL</measure>
    <time_frame>2 years follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Include evaluation of the next parameters: Complete and partial remission rates for all patients Response duration for responder patients PFS for all patients Overall survival for all patients Acute and long-term toxicity</measure>
    <time_frame>2 years follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>MALT LYMPHOMA</condition>
  <arm_group>
    <arm_group_label>Rituximab and Bendamustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab and Bendamustine</intervention_name>
    <description>Rituximab 375 mg/m2 iv. day 1 Bendamustine 90 mg/m2 iv. day 1 and 2</description>
    <arm_group_label>Rituximab and Bendamustine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proven diagnosis of CD20-positive marginal zone B-cell lymphoma of MALT
             type arisen at any extranodal site (WHO classification)

          2. Any stage (Ann Arbor I-IV)

          3. The novo disease en any extranodal site. For primary gastric or cutaneous lymphoma,
             local/specific previous treatment is accepted, just following the below criteria:

               1. Cutaneous lymphoma: recurrent lymphoma after local therapy

               2. Gastric lymphoma:

             b1. H. pylori-negative cases, either de novo (non pre-treated) or at relapse following
             local therapy (i.e., surgery, radiotherapy or antibiotics).

             b2. H. pylori-positive cases at diagnosis, who failed antibiotic therapy, including
             patients with: clinical (endoscopic) and histological evidence of disease progression
             at any time post H. pylori eradication; stable disease with persistent lymphoma at 1
             year post H. pylori eradication; relapse (without H. pylori re-infection), after a
             remission; patients who failed either first line antibiotics or further local
             treatment (surgery or radiotherapy)

          4. No evidence of histologic transformation to a high grade lymphoma

          5. Measurable or evaluable disease

          6. Age &gt;18 and &lt;85

          7. ECOG performance status 0-2

          8. Life expectancy of at least 1 year

          9. Written informed consent given according to national/local regulations

        Exclusion Criteria:

          1. Prior chemotherapy or prior immunotherapy with any anti-CD20 monoclonal antibody

          2. Prior radiotherapy in the last 6 weeks

          3. Corticosteroids during the last 28 days, unless prednisone chronically administered at
             a dose &lt;20 mg/day for indications other than lymphoma or lymphoma-related symptoms

          4. Major impairment of renal function (serum creatinine &gt; 2,5 x upper normal) or liver
             function (ASAT/ALAT &lt;2,5 x upper normal, total bilirubin &lt;2,5x upper normal), unless
             due to lymphoma involvement.

          5. Impairment of bone marrow function (WBC &lt;3.0x109/L, ANC &lt;1.5x109/L, PLT &lt;100x109/L),
             unless due to lymphoma involvement

          6. Evidence of clinically significant cardiac, neurological or metabolic disease, unless
             due to lymphoma involvement

          7. Evidence of symptomatic central nervous system (CNS) disease

          8. Active HBV and/or HCV infection

          9. Known HIV infection

         10. Prior diagnosis of neoplasm within 5 years, except cervical intraepithelial neoplasia
             type 1 (CIN1) or localized non-melanomatous skin cancer

         11. Any psychiatric disease potentially hampering compliance with the study protocol and
             follow-up schedule

         12. Potential to attend regular visits to the hospital, on an outpatient regimen

         13. Hypersensibility to any compound of the study medication.

         14. Non appropriate contraceptive method in women of childbearing potential or men

         15. Treatment with any drug under research within 30 days previous to start the study
             medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Montalbán, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ramon y Cajal Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Salar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital del Mar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Muntañola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mutua de Terrassa Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mª José Rodríguez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Canarias</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María José Terol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Manuel Sancho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO Hospital Germans Trias i Pujol</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva Domingo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO Hospital Durans i Reynals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Grande Carlos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>12 de Octubre Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Panizo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Universitaria Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel Canales, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>La Paz Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raquel Oña, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Anderson Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reyes Arranz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>La Princesa Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dolores Caballero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Unisversitario de Salamanca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Luis Bello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario Universitario de Santiago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joan Bargay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Son Llátzer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Palomera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico de Zaragoza</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franciaco Javier Peñalver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación Hospital Alcorcón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eulogio Conde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Marqués de Valdecilla Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Javier Sánchez-Blanco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Morales Meseguer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Concepción Nicolás, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central de Asturias Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO-Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08918</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO-Hospital Durans i Reynals</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Fundación Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llátzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Mallorca</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Sta. Cruz de Tenerife</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital MD Anderson</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Zaragoza &quot;Lozano Blesa&quot;</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2009</study_first_submitted>
  <study_first_submitted_qc>November 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <last_update_submitted>September 6, 2016</last_update_submitted>
  <last_update_submitted_qc>September 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD 20 positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

